24/7 Market News Snapshot 06 January, 2025 – NanoVibronix, Inc. Common Stock (NASDAQ:NAOV)

January 6, 2025

DENVER, Colo., 06 January, 2025 (247marketnews.com) – (NASDAQ:NAOV) are discussed in this article.
NanoVibronix, Inc. has emerged as a prominent player in the medical device industry, experiencing significant market interest following the completion of the first phase of a randomized control trial for its UroShield® product. Trading at $0.63, NAOV stock surged by over 36% during yesterday’s session, closing at $0.819. The impressive trading volume of 9.49 million shares underscores strong investor enthusiasm surrounding the innovative healthcare solutions offered by the company.

The trial, conducted at a leading research university, aims to evaluate UroShield®’s effectiveness in enhancing patients’ quality of life by addressing critical issues such as urinary tract infections, catheter blockages, and pain management related to long-term urinary catheter use. The successful completion of this pilot phase marks an essential step forward for NanoVibronix, positioning the research team to embark on a larger, more comprehensive study anticipated to begin in 2025. Brian Murphy, CEO of NanoVibronix, expressed optimism about the trial’s outcomes, which will support the forthcoming U.S. market launch of UroShield®, pending regulatory approval.

The initiative aligns with the company’s dedication to advancing its patented low-intensity Surface Acoustic Wave technology, known for its unique applications in medical treatment. Dr. Lona Mody, a principal investigator in the trial, praised the achievements thus far, particularly in optimizing recruitment strategies and data collection processes.

As NanoVibronix builds on its successes in international markets, it continues to innovate and address unmet medical needs, demonstrating significant potential to transform patient care in both home and clinical settings. This commitment to research and development not only bolsters investor confidence but also highlights the company’s potential impact on chronic condition management in the evolving healthcare landscape.

Related news for (NAOV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.